Haws, R., Clément, K., Dollfus, H., Han, J. C., Haqq, A. M., Martos-Moreno, G. A., . . . Argente, J. (2021). A Phase 3 Trial in Participants With Obesity Due to Bardet-Biedl Syndrome or Alström Syndrome: Efficacy and Safety of the Melanocortin 4 Receptor Agonist Setmelanotide. J Endocr Soc.
Styl ChicagoHaws, Robert, et al. "A Phase 3 Trial in Participants With Obesity Due to Bardet-Biedl Syndrome or Alström Syndrome: Efficacy and Safety of the Melanocortin 4 Receptor Agonist Setmelanotide." J Endocr Soc 2021.
Citace podle MLAHaws, Robert, et al. "A Phase 3 Trial in Participants With Obesity Due to Bardet-Biedl Syndrome or Alström Syndrome: Efficacy and Safety of the Melanocortin 4 Receptor Agonist Setmelanotide." J Endocr Soc 2021.